These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 28960254)

  • 1. Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study.
    Nakagawa H; Nemoto O; Igarashi A; Nagata T
    Br J Dermatol; 2018 Feb; 178(2):424-432. PubMed ID: 28960254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis.
    Nakagawa H; Nemoto O; Igarashi A; Saeki H; Oda M; Kabashima K; Nagata T
    J Allergy Clin Immunol; 2019 Dec; 144(6):1575-1583. PubMed ID: 31425780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis.
    Nakagawa H; Nemoto O; Yamada H; Nagata T; Ninomiya N
    J Dermatol; 2018 Jun; 45(6):701-709. PubMed ID: 29665062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.
    Nakagawa H; Nemoto O; Igarashi A; Saeki H; Kaino H; Nagata T
    J Am Acad Dermatol; 2020 Apr; 82(4):823-831. PubMed ID: 32029304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis.
    Nakagawa H; Nemoto O; Igarashi A; Saeki H; Murata R; Kaino H; Nagata T
    J Dermatol; 2020 Feb; 47(2):114-120. PubMed ID: 31820485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial.
    Reitamo S; Harper J; Bos JD; Cambazard F; Bruijnzeel-Koomen C; Valk P; Smith C; Moss C; Dobozy A; Palatsi R;
    Br J Dermatol; 2004 Mar; 150(3):554-62. PubMed ID: 15030341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.
    Bissonnette R; Papp KA; Poulin Y; Gooderham M; Raman M; Mallbris L; Wang C; Purohit V; Mamolo C; Papacharalambous J; Ports WC
    Br J Dermatol; 2016 Nov; 175(5):902-911. PubMed ID: 27423107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study.
    Nakagawa H; Nemoto O; Igarashi A; Saeki H; Kabashima K; Oda M; Nagata T
    J Am Acad Dermatol; 2021 Oct; 85(4):854-862. PubMed ID: 34118298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.
    Eichenfield LF; Gower RG; Xu J; Alam MS; Su JC; Myers DE; Sanders P; Vlahos B; Zang C; Lan J; Werth J
    Am J Clin Dermatol; 2023 Jul; 24(4):623-635. PubMed ID: 37184828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
    Paller AS; Tom WL; Lebwohl MG; Blumenthal RL; Boguniewicz M; Call RS; Eichenfield LF; Forsha DW; Rees WC; Simpson EL; Spellman MC; Stein Gold LF; Zaenglein AL; Hughes MH; Zane LT; Hebert AA
    J Am Acad Dermatol; 2016 Sep; 75(3):494-503.e6. PubMed ID: 27417017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial.
    Doss N; Reitamo S; Dubertret L; Fekete GL; Kamoun MR; Lahfa M; Ortonne JP
    Br J Dermatol; 2009 Aug; 161(2):427-34. PubMed ID: 19416227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of PAC-14028 cream - a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild-to-moderate atopic dermatitis: a phase IIb randomized trial.
    Lee YW; Won CH; Jung K; Nam HJ; Choi G; Park YH; Park M; Kim B
    Br J Dermatol; 2019 May; 180(5):1030-1038. PubMed ID: 30623408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis.
    Reitamo S; Rustin M; Ruzicka T; Cambazard F; Kalimo K; Friedmann PS; Schoepf E; Lahfa M; Diepgen TL; Judodihardjo H; Wollenberg A; Berth-Jones J; Bieber T;
    J Allergy Clin Immunol; 2002 Mar; 109(3):547-55. PubMed ID: 11898005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis.
    Reitamo S; Ortonne JP; Sand C; Cambazard F; Bieber T; Fölster-Holst R; Vena G; Bos JD; Fabbri P; Groenhoej Larsen C;
    Br J Dermatol; 2005 Jun; 152(6):1282-9. PubMed ID: 15948994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study.
    Hanifin JM; Ellis CN; Frieden IJ; Fölster-Holst R; Stein Gold LF; Secci A; Smith AJ; Zhao C; Kornyeyeva E; Eichenfield LF
    J Am Acad Dermatol; 2016 Aug; 75(2):297-305. PubMed ID: 27189825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, efficacy, and pharmacokinetics of delgocitinib ointment in infants with atopic dermatitis: A phase 3, open-label, and long-term study.
    Nakagawa H; Igarashi A; Saeki H; Kabashima K; Tamaki T; Kaino H; Miwa Y
    Allergol Int; 2024 Jan; 73(1):137-142. PubMed ID: 37100717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of tacrolimus ointment in pediatric Patients with moderate to severe atopic dermatitis.
    Singalavanija S; Noppakun N; Limpongsanuruk W; Wisuthsarewong W; Aunhachoke K; Chunharas A; Wananukul S; Akaraphanth R
    J Med Assoc Thai; 2006 Nov; 89(11):1915-22. PubMed ID: 17205874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study.
    Schachner LA; Lamerson C; Sheehan MP; Boguniewicz M; Mosser J; Raimer S; Shull T; Jaracz E;
    Pediatrics; 2005 Sep; 116(3):e334-42. PubMed ID: 16140675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter trial of the efficacy and safety of 0.03% tacrolimus ointment for atopic dermatitis in Korea.
    Won CH; Seo PG; Park YM; Yang JM; Lee KH; Sung KJ; Park CW; Kim DW; Chang HS; Won YH; Kim KH
    J Dermatolog Treat; 2004 Jan; 15(1):30-4. PubMed ID: 14754647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.
    Guttman-Yassky E; Blauvelt A; Eichenfield LF; Paller AS; Armstrong AW; Drew J; Gopalan R; Simpson EL
    JAMA Dermatol; 2020 Apr; 156(4):411-420. PubMed ID: 32101256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.